DEM Biopharma, Inc. Employee Directory
Biotechnology ResearchUnited States11-50 Employees
DEM BioPharma is pioneering the next generation of cancer therapeutics. Our lead program, DEM301, is an antibody-drug conjugate (ADC) targeting a novel extracellular protein that is overexpressed in gastrointestinal and other malignancies.